Key Takeaways:
- FDA proposes excluding semaglutide, tirzepatide, and liraglutide from 503B bulk list, finding no clinical need for large-scale compounding
- Public comment period runs through June 29, 2026, before FDA makes final determination
- Could end $150-300 monthly compounding access that served millions during shortage period versus $1000+ branded pricing
The FDA has taken its most significant step yet to restrict affordable GLP-1 access by proposing to permanently block large-scale compounding of the most popular weight loss medications. The agency's April 30 announcement could fundamentally reshape how people access these life-changing treatments.
FDA Targets Large-Scale Compounding Operations
On April 30, 2026, the U.S. Food and Drug Administration announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances. This regulatory mechanism has allowed large compounding facilities to produce these medications at scale during and after the drug shortages that began in 2022.
The 503B bulks list identifies bulk drug substances that outsourcing facilities may use in compounding under section 503B of the Federal Food, Drug, and Cosmetic Act ("FD&C Act"). In most cases, outsourcing facilities cannot compound drugs using bulk drug substances unless the substance appears on the 503B bulks list or the compounded drug is on the FDA's drug shortage list at the time of compounding, distribution, and dispensing.
"When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need," said FDA Commissioner Marty Makary, M.D., M.P.H. "The FDA carefully reviewed the nominations it received and did not identify sufficient evidence to include semaglutide, tirzepatide and liraglutide on the 503B bulks list."
How This Impacts Your Access and Costs
Compounding of GLP-1 medications quickly became a massive industry, as pharmacies and telehealth firms offered these medications at substantially lower prices than the branded products. The proposal could dramatically impact the millions of people who have relied on compounded alternatives through telehealth providers.
Demand-driven shortages beginning in 2022 enabled widespread compounding at approximately $150 to $300 per month vs more than $1000 branded pricing, until the FDA declared shortages resolved and imposed wind-down enforcement deadlines. For many patients, compounded versions became their only affordable path to treatment with semaglutide and other GLP-1 medications.
Currently, tirzepatide and semaglutide do not appear on either the 503B bulks list or the drug shortage list. The significance of this proposal is that it would close one of the few remaining legal avenues for 503B outsourcing facilities to be able to resume large-scale compounding of these drugs.
If finalized, the proposal could significantly impact telehealth firms that have relied on 503B outsourcing facilities to produce these medications at scale.
Safety Concerns Drive Regulatory Action
The FDA's decision comes amid mounting safety concerns about compounded products. As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials—some of which required hospitalization.
Litigation by Novo Nordisk alleges some compounded semaglutide contained impurities up to 86%, highlighting risks of contamination, variable potency, and severe hypersensitivity reactions including anaphylaxis. These quality control issues have reinforced the FDA's enforcement focus on protecting your safety.
Mass compounding of GLP-1 medications has been linked to hundreds of adverse events — including sepsis, liver injury, and hospitalizations — as well as recalls involving thousands of contaminated or improperly dosed vials. With FDA-approved drugs no longer on FDA's shortage list, there is no legal or clinical justification for outsourcing facilities to continue compounding these substances.
Limited Compounding Options May Still Exist
Importantly, this proposal does not directly alter the legal framework for 503A compounding pharmacies. Section 503A pharmacies operate under a separate statutory provision and compound drugs pursuant to individual patient-specific prescriptions under state board of pharmacy oversight. They do not rely on the 503B bulks list to authorize their compounding activities, and the proposed exclusion of semaglutide, tirzepatide, and liraglutide from that list has no independent legal effect on their operations.
However, compounding of semaglutide or tirzepatide by 503A pharmacies may therefore be permissible only where there is a documented, individualized medical necessity for a formulation that is not merely a copy of the FDA-approved product — such as an allergy to a specific inactive ingredient in the branded version, a clinically justified need for a different concentration not commercially available, or a dosage form modification required for a specific patient population. Patient preference and cost savings alone are insufficient justifications.
This means if you have specific medical needs that can't be met by branded medications, smaller compounding pharmacies may still be able to help you with customized formulations.
What This Means for You
If you're currently using compounded GLP-1 medications, this proposal could significantly impact your access and costs. While the rule isn't final yet, you can start exploring your options now. Check if you qualify for manufacturer savings programs or patient assistance programs for brand medications like Wegovy or Zepbound. Many people don't realize these programs can reduce costs to $25-50 per month for eligible patients.
You can also work with providers who offer comprehensive support in navigating insurance coverage and finding the most cost-effective treatment options. The landscape is changing rapidly, and having an experienced team on your side can make the difference between continuing treatment and losing access. Consider connecting with specialists at GLP-1 clinics who understand both the regulatory environment and your individual needs.
Take action during the public comment period, which runs through June 29, 2026. Your voice matters in this regulatory process, especially if you've relied on compounded medications or experienced barriers to accessing branded versions.
Sources
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List - FDA press announcement from April 30, 2026
- Federal Register Notice - Official proposal with public comment period through June 29, 2026
- FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs - Legal analysis of the proposal's implications
- FDA Moves to Permanently Close the Door on Compounded GLP-1s - Industry analysis of safety concerns and enforcement actions